Cellectis sets Q3 2026 results for November 12

The investor call and webcast will include a business-activities update as well as the quarterly results.

Available on EDGAR 11/09/2026 - 04:35 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:35 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cellectis S.A. will report third-quarter 2026 financial results for the quarter ended September 30, 2026, on November 12, 2026, after the U.S. market close. An investor conference call and webcast will follow on November 13 at 8:00 a.m. ET / 2:00 p.m. CET, covering the results and a business-activities update.

Key Figures

Third-quarter results date: November 12, 2026 Quarter ended: September 30, 2026 Investor call and webcast: November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET

3 metrics

Third-quarter results date November 12, 2026 Results for the third quarter of 2026

Quarter ended September 30, 2026 Third-quarter 2026 results

Investor call and webcast November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET Results and business-activities update

Key Terms

genome engineering, base editing, epigenetic editing

3 terms

genome engineering technical

"genome engineering company developing genetic medicines"

Genome engineering is the deliberate editing of an organism’s DNA to add, remove or change specific genetic instructions—like correcting typos in a recipe or swapping a paragraph in an instruction manual. For investors, it matters because these edits can create new medicines, crops or industrial processes, driving potential revenue, patent value and regulatory risk; success or failure in development and approval can substantially affect a biotech company’s prospects.

base editing technical

"gene editing, base editing, epigenetic editing"

A laboratory method that changes single “letters” in DNA to correct or alter genes without cutting the entire strand, like fixing a typo in a sentence rather than tearing out the page. It matters to investors because it promises faster, more precise treatments with potentially lower development costs and different safety and regulatory profiles than traditional gene therapies, which can speed clinical progress or create new commercial opportunities — and risks.

epigenetic editing technical

"gene editing, base editing, epigenetic editing"

Epigenetic editing is a method that changes chemical tags on DNA or its packaging to turn specific genes on or off without altering the underlying genetic code. Think of it like adding or removing sticky notes on an instruction manual to change which instructions are read. For investors, it matters because this approach can enable precise, potentially reversible treatments for diseases with different safety and regulatory profiles than permanent gene edits, affecting clinical value and commercial potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: November 9, 2026

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

EXHIBIT INDEX

Exhibit		Title
99.1		Press Release dated November 9, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Cellectis S.A.
		(Registrant)
Date: November 9, 2026		/s/ André Choulika
		André Choulika
		Chief Executive Officer

EXHIBIT 99.1

Cellectis to Report Third Quarter Financial Results on November 12, 2026

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.

The publication will be followed by an investor conference call and webcast on Friday, November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET. The call will include the Company’s third quarter 2026 results and an update on business activities. Details for the call are as follows:

Dial in information:
Toll Free US & Canada: +1-833-354-6854
US/International Toll: +1-785-838-9343
Conference ID: CLLSQ3
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1780016&tp_key=925efa50d7

About Cellectis

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment. Leveraging decades of expertise in programmable DNA-binding proteins, the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generation of genetic medicines designed to move beyond disease management and toward lasting therapeutic impact.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit  www.cellectis.com  and follow Cellectis on  LinkedIn  and  X.  

For further information on Cellectis, please contact:         
     
Media contacts:              
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com         
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      

Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• Q3 2026 announcement PR_ENGLISH.pdf (https://ml.globenewswire.com/Resource/Download/0b14096f-beec-4196-95d8-43124085acf4)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 3.7 KB